Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

Is ‘BerkshAmazMorgan’ Testing a Cure for What Ails US Healthcare?

Posted by Pratap Khedkar on Thu, Mar 29, 2018

Paul Darling co-wrote this blog post with Pratap Khedkar.

This is the second post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

The U.S. healthcare system is broken. Most healthcare stakeholders now are willing to admit that, and many are actively trying to fix it—or at least starting to talk about what it would take to do so. Many of the recent consolidations and vertical integrations are the involved parties’ attempts at solving for links in the healthcare chain that they previously had no access to, or influence over. Now three giants from corporate America are looking to wade deeper into healthcare delivery to see if they can make some fixes for their employees—and for themselves.

Read More

Topics: Pratap Khedkar, healthcare, vertical integration, healthcare ecosystem, Paul Darling, Amazon, pharmaceutical ads, data and analytics, data strategy, BerkshAmazMorgan, behavior modification, preventive care, healthcare model, employee health and wellness

What’s ‘BerkshAmazMorgan’ Really Capable Of?

Posted by Howard Deutsch on Tue, Feb 20, 2018

Bill Coyle, Paul Darling and Pratap Khedkar co-authored this post with Howard Deutsch.

This is the first post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

Look! Out in the distance! What’s that creature that’s destroying everything in its path? Why, it’s the scariest three-headed monster this side of Cerberus! It’s… it’s… it’s BerkshAmazMorgan! Will any of us be safe from this dreaded, rampaging beast?

Read More

Topics: Bill Coyle, Pratap Khedkar, Health Outcomes, healthcare, vertical integration, healthcare ecosystem, Paul Darling, Howard Deutsch, Amazon, collaboration, Berkshire Hathaway, JPMorgan Chase, corporatization, BerkshAmazMorgan, employees, healthcare costs

Five Steps to Address the Pain Points of Co-Pay Accumulator Programs

Posted by Howard Deutsch on Wed, Jan 31, 2018

In the cat-and-mouse co-pay card game, payers have made their next move. Pharmacy benefit managers have been promoting “co-pay accumulator” programs to plan sponsors as a way to reduce specialty drug spending. Left alone, these programs will result in confused patients who are less likely to adhere to their medications, and high costs for pharmaceutical manufacturers. Pharma companies need to respond.

Read More

Topics: pharmaceutical industry, Pharma, healthcare, payers, manufacturers, PBMs, pricing, patient centricity, co-pay accumulator programs, health insurance, pharmacy benefit managers, co-pay cards, deductible

Healthcare’s Misalignment Means Missed Opportunities for All Stakeholders

Posted by Pratap Khedkar on Mon, Nov 13, 2017

Bill Coyle co-authored this blog post with Pratap Khedkar.

The wheels of a car in need of an alignment point in different directions and effectively begin working against each other. As a result, the vehicle works inefficiently, which negatively impacts the driver’s experience and increases the financial pain he feels at the pump. If the problem is ignored for too long, his ability to safely operate the vehicle can become compromised. And when the car is operating at a high speed, the misaligned tires could have devastating consequences, making steering difficult and potentially leading to a crash.

Read More

Topics: customer experience, customer centricity, Pharma, healthcare, healthcare ecosystem, value-based care, patient centricity, pharma companies

Highlights From ZS’s 2017 European Summit: What Industry Leaders Really Think About Patient Centricity in Pharma

Posted by Giorgio Lentini on Tue, Oct 31, 2017

Robert Selman and Ausrine Vaisvilaite co-wrote this blog post with Giorgio Lentini. 

Are we already patient-centric simply by talking about patients? Do patients define themselves by their medical conditions or by their roles in life as parents, family members or colleagues?

These were just some of the many questions discussed amongst participants at ZS’s European Summit, which took place in Basel, Switzerland, on Oct. 12.

Read More

Topics: Pharma, Pharma Industry, healthcare, Europe, EU, patient centricity, RWE, real-world evidence, patient centricity in R&D, ZS European Summit

Subscribe to The Active Ingredient
SUBSCRIBE

Get 'THE ACTIVE INGREDIENT' Updates

Subscribe to receive email notifications whenever new blog posts are published.

×